CDK inhibitors may increase survival for ER-positive metastatic breast cancer patients

https://www.facingourrisk.org/XRAY/CDK-inhibitor-improves-survival-for-metastatic-breast-cancer

Full article: https://www.nejm.org/doi/10.1056/

The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19)

Questions To Ask Your Health Care Provider

Is my cancer ER/PR-positive and Her2-negative?
Am I candidate for ribociclib plus hormonal therapy?
As a premenopausal woman, what is the best therapy for my breast cancer?
What are the benefits and risks of hormonal therapy?
What are the benefits and risks of CDK4/6 inhibitor therapy?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.